fashion -WSS

fashion

author：focus 2025-09-27 21:55:27 - browse：64

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Did you have Obamacare on your GOP debate bingo card?

entertainment

WSS

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Covid vaccines: Private market messier than government rollout

Medicaid, Medicare dual

Address the ethical violations that led to 'Three Identical Strangers'

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

knowledge

fashion

entertainment

How one medical school became remarkably diverse

UpToDate has a racism problem: Dr. Stanley Goldfarb

Trump demands the U.S. pay no more for drugs than other countries … again

STAT wants to know your pick for a great summer read or listen

Trump demands the U.S. pay no more for drugs than other countries … again

Biogen shutters digital health group, ends Apple study, in cost cutting move

In age of alternative facts, a scholarly course on calling out crap

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Apple is now the first public company to be valued at $3 trillion

WHO recommends dropping component of many flu vaccines

knowledge

Beware reading your test results before your doctor does

What affirmative action's end means to a medical student

Why do women spend more than men on medical expenses?

How the Dana

STAT wants to know your pick for a great summer read or listen

The wait for US passports is creating travel purgatory and snarling summer plans

leisure time

entertainment

entertainment

hotspot